REVIVER® HELPS DRIVE THE SPIRIT OF GIVING THIS HOLIDAY SEASONBlake Lively's claims put spotlight on 'sinister' Hollywood tactics

Jimmy Carter's Funeral Service, Public Observances: What to KnowGreen Bay's recent dominance on defense has Packers believing they can make a deep playoff run

Banque Cantonale Vaudoise cut its holdings in shares of The J. M. Smucker Company ( NYSE:SJM – Free Report ) by 88.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 303 shares of the company’s stock after selling 2,375 shares during the period. Banque Cantonale Vaudoise’s holdings in J. M. Smucker were worth $37,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds also recently added to or reduced their stakes in SJM. Axxcess Wealth Management LLC acquired a new position in shares of J. M. Smucker in the 1st quarter valued at about $428,000. Quadrature Capital Ltd acquired a new position in J. M. Smucker in the first quarter valued at approximately $554,000. BOKF NA boosted its position in J. M. Smucker by 20.7% in the 1st quarter. BOKF NA now owns 8,209 shares of the company’s stock worth $1,024,000 after purchasing an additional 1,408 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of J. M. Smucker by 0.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 145,306 shares of the company’s stock worth $18,291,000 after purchasing an additional 1,239 shares during the period. Finally, Mount Yale Investment Advisors LLC purchased a new position in shares of J. M. Smucker during the 1st quarter valued at approximately $397,000. 81.66% of the stock is owned by hedge funds and other institutional investors. J. M. Smucker Price Performance Shares of NYSE SJM opened at $113.30 on Friday. The stock has a market capitalization of $12.06 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 3.19 and a beta of 0.25. The J. M. Smucker Company has a 52 week low of $105.69 and a 52 week high of $134.62. The firm has a 50-day simple moving average of $116.57 and a 200-day simple moving average of $115.53. The company has a quick ratio of 0.25, a current ratio of 0.55 and a debt-to-equity ratio of 0.87. J. M. Smucker Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 15th will be issued a $1.08 dividend. This represents a $4.32 annualized dividend and a yield of 3.81%. The ex-dividend date of this dividend is Friday, November 15th. J. M. Smucker’s payout ratio is currently 61.10%. Wall Street Analysts Forecast Growth Several analysts recently commented on SJM shares. TD Cowen dropped their price target on shares of J. M. Smucker from $135.00 to $132.00 and set a “buy” rating on the stock in a research report on Thursday, August 29th. DA Davidson restated a “neutral” rating and set a $121.00 target price on shares of J. M. Smucker in a research report on Thursday, August 29th. Bank of America reduced their price target on J. M. Smucker from $130.00 to $122.00 and set a “neutral” rating for the company in a report on Thursday, August 29th. Barclays dropped their price objective on J. M. Smucker from $123.00 to $121.00 and set an “equal weight” rating on the stock in a report on Friday, August 30th. Finally, Stifel Nicolaus lowered J. M. Smucker from a “buy” rating to a “hold” rating and decreased their target price for the company from $135.00 to $125.00 in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $127.09. View Our Latest Stock Analysis on SJM About J. M. Smucker ( Free Report ) The J. M. Smucker Company manufactures and markets branded food and beverage products worldwide. It operates in three segments: U.S. Retail Pet Foods, U.S. Retail Coffee, and U.S. Retail Consumer Foods. The company offers mainstream roast, ground, single serve, and premium coffee; peanut butter and specialty spreads; fruit spreads, toppings, and syrups; jelly products; nut mix products; shortening and oils; frozen sandwiches and snacks; pet food and pet snacks; and foodservice hot beverage, foodservice portion control, and flour products, as well as dog and cat food, frozen handheld products, juices and beverages, and baking mixes and ingredients. Featured Stories Receive News & Ratings for J. M. Smucker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for J. M. Smucker and related companies with MarketBeat.com's FREE daily email newsletter .Roivios Initiates Landmark Study to Demonstrate Safety and Efficacy of an Innovative Renal Assist Device for Cardiac Surgery Patients With Kidney Disease NASSAU, Bahamas , Dec. 19, 2024 /PRNewswire/ -- Roivios , a pioneering clinical-stage medical device company dedicated to revolutionizing kidney health, proudly announces that its research and development arm, 3ive Labs, has secured approval for an Investigational Device Exemption (IDE) from the FDA. This approval paves the way for a pivotal trial of the JuxtaFlow Renal Assist Device (RAD), marking a transformative step forward in enhancing outcomes for cardiac surgery patients with renal insufficiency. The GRADIENT ( G roundbreaking R enal A ssist D evice I ntervening to EN hance cardio T horacic surgery outcomes) trial is designed to address the critical need for renal support among cardiac surgery patients undergoing cardiopulmonary bypass (CPB). These patients often face increased risks of postoperative complications, such as worsening renal dysfunction, which can lead to extended ICU stays and increased mortality. "The GRADIENT Trial offers an invaluable opportunity to further explore renal support during cardiac surgery," said Dr. Evelio Rodriguez , a renowned heart surgeon at Ascension Saint Thomas in Nashville, TN , and the National Principal Investigator of the GRADIENT trial. "The JuxtaFlow device offers new hope for some of our most vulnerable patients." JuxtaFlow RAD is an innovative device designed to potentially improve kidney function during times of acute stress. By applying a gentle suction to the kidney's outlet, it aims to enhance blood filtration more efficiently. This groundbreaking approach was recognized with an FDA Breakthrough Device Designation in April. The GRADIENT study will be a prospective, multicenter, randomized, controlled, open-label trial that plans to enroll patients with renal insufficiency (eGFR 15-60 ml/min) undergoing elective or urgent cardiac surgery requiring CPB. The study seeks to evaluate the safety and effectiveness of the JuxtaFlow RAD to sustain or enhance renal function during and following CPB surgery. "Achieving Breakthrough Device Designation was instrumental in securing IDE approval," noted John Erbey , Chief Executive Officer at Roivios. "This initiative is the culmination of a decade of technological and clinical advancements in addressing kidney disease management challenges. Our ongoing dialogue with the FDA is paving the way for more effective management, empowering patients to thrive. We are eager to commence IDE enrollment and explore the JuxtaFlow RAD's potential to improve surgical outcomes and enhance patient quality of life." For more information about Roivios and the JuxtaFlow Renal Assist Device, please visit Roivios.com . About JuxtaFlow RAD The JuxtaFlow RAD is a pioneering investigational device set to transform kidney support therapy. Acknowledging the harmful effects of fluid accumulation and pressure on the kidneys, Roivios has advanced beyond traditional blood filtration methods that can further stress the kidneys. By applying mild, controlled negative pressure within the kidney's collecting system, the device has the potential to maintain and improve filtration and support recovery. This novel approach holds promise for a compelling value proposition by preserving kidney function and expediting patient recovery, ultimately reducing hospital stays and associated costs. Equipped with a proprietary specialized catheters and pump, the device optimizes kidney function during critical recovery periods, such as post-surgery. Currently, the JuxtaFlow RAD is under investigation and is not available for sale in any geography. About Roivios Roivios is a clinical-stage medical device company committed to pioneering solutions for kidney health. Our lead product, the JuxtaFlow Renal Assist Device (RAD), is designed to preserve kidney function and offer a proactive approach to managing kidney disease. We aim to demonstrate improved renal outcomes, potentially reducing the need for dialysis, and lowering healthcare costs. Holding proprietary patents in key kidney technologies, we aim to revolutionize kidney disease management. With plans to extend its application beyond kidney disease to various medical settings, Roivios is preparing for a transformative U.S. launch, aiming to redefine kidney disease management and improve patient quality of life. Discover more at roivios.com . This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ significantly. Media Contact : Kelly Krueger , Krueger PR, kelly@kruegerpr.com View original content to download multimedia: https://www.prnewswire.com/news-releases/fda-grants-ide-approval-for-the-pivotal-trial-of-the-juxtaflow-renal-assist-device-rad-302336698.html SOURCE Roivios, ltd

( MENAFN - Chainwire) Dubai, UAE, December 20th, 2024, Chainwire On August 28, 2024, Sixteen members of the MEET48 idol group captivated audiences at WebX 2024 with their singing and dancing performances. By the end of the year, MEET48 will have performed across multiple key markets, including Hong Kong, Dubai, Japan, Singapore, and Thailand, highlighting their increasing influence in the global entertainment industry. Blending the charm of traditional idol performances with emerging Web3 technologies, MEET48 aims to redefine fan engagement through innovative digital platforms and decentralized ecosystems. Mars Protocol Beta Launch Announced for Q4 2024 On November 29, MEET48 announced the Beta testing of its Mars Protocol, a new platform within the BNB Chain ecosystem set to officially launch in Q1 2025. Mars Protocol introduces the first AI-driven idol platform, combining elements of AI-Agent technology with Meme coins. Positioned as a next-generation tool in the Web3 idol economy, it integrates text, image, music, and voice-generation technologies to enable dynamic content creation and fan engagement. Mars Protocol also supports the issuance of Meme coins by virtual idols, providing creators and fans with novel ways to interact and engage in decentralized communities. MEET48.ai and the Future of the AI Idol Ecosystem In January 2025, MEET48.ai will launch with over 250 AI idol agents, each capable of issuing Meme coins through Mars Protocol. The platform enables content creators and KOLs to design and deploy their own AI-driven idols, fostering co-creation and collaboration. MEET48.ai further expands its functionality with the AIShowBox tool, allowing users to create custom content and participate in an active DAO-driven community. With integrated text-to-image, text-to-music, and music-to-dance capabilities, the platform enhances user creativity while driving engagement through incentivized rewards. Building a Decentralized Fan Economy With the global fan economy valued in the trillions, MEET48 leverages Web3 technologies to enable decentralized participation and collaboration. Fans can support their favorite idols by purchasing and trading IDOL tokens on the platform's decentralized exchange. Token interactions power voting competitions, content releases, and live events, reinforcing the connection between fans and virtual idols. The MEET48 ecosystem has already achieved significant milestones, including a peak of 537,000 daily active users and 702,000 unique wallets during its“2024 GIPR2” event. On July 22, 2024, MEET48 recorded a 24-hour trading volume of $2.83 million. Participation in the MVB Accelerator Program Recognizing MEET48's strong on-chain performance and innovative approach, the platform was invited to join the 8th season of the MVB Accelerator Program on October 30, 2024. Organized by BNB Chain in collaboration with Binance Labs and CMC Labs, the program supports promising blockchain projects with strategic resources and guidance. How to Cultivate A Virtual Idol MEET48 provides users with the tools to create and develop AI-powered virtual idols on the blockchain. Through the platform's Mars Protocol, users can design virtual idols, tokenize them, and issue Meme coins for community engagement. These AI idols can participate in entertainment, gaming, and social ecosystems, interacting with fans and generating content. Users can enhance idol visibility and popularity by actively promoting tokens, engaging in community events, and participating in DEX trading. Mars Protocol supports large-scale idol voting events, allowing fans to influence idol rankings. Revenue from these events is reinvested into the ecosystem, funding media production, music videos, live streams, and virtual concerts to further develop the idols' presence. Innovating at the Intersection of Entertainment and Web3 MEET48's team brings deep experience in idol entertainment and fan economies, having created one of the largest female idol groups globally. Supported by a $50 million investment in R&D, the team has developed advanced AI models for content creation, including text-to-music and music-to-dance generation. Future applications of MEET48's technology include gaming products, virtual concerts, and more, further expanding the platform's influence within the entertainment and Web3 sectors. About MEET48 MEET48 is recognized as one of the largest Web3 application project teams globally, boasting a 500-member technical and R&D team and a regional operations network covering Singapore, Hong Kong, Taipei, Tokyo, Seoul, and Dubai. MEET48 aims to achieve mass adoption of Web3 technology through an AI UGC content ecosystem focused on AIGC (Animation, Idol, Game, and Comics) and a graphical, intelligent metaverse social foundation tailored to Gen Z entertainment trends. Official Website: https://www.meet48.xyz/ MENAFN19122024007842016840ID1109014757 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

ALTOONA, Pa. — After UnitedHealthcare’s CEO was gunned down on a New York sidewalk, police searched for the masked gunman with dogs, drones and scuba divers. Officers used the city's muscular surveillance system. Investigators analyzed DNA samples, fingerprints and internet addresses. Police went door-to-door looking for witnesses. When an arrest came five days later, those sprawling investigative efforts shared credit with an alert civilian's instincts. A Pennsylvania McDonald's customer noticed another patron who resembled the man in the oblique security-camera photos that New York police had publicized. Deputy Commissioner of Operations Kaz Daughtry speaks during a press conference regarding the arrest of suspect Luigi Mangione, Monday, Dec. 9, 2024, in Hollidaysburg, Pa., in the fatal shooting of UnitedHealthcare CEO Brian Thompson. (AP Photo/Ted Shaffrey) Luigi Nicholas Mangione, a 26-year-old Ivy League graduate from a prominent Maryland real estate family, was arrested Monday in the killing of Brian Thompson, who headed one of the United States’ largest medical insurance companies. He remained jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. By late evening, prosecutors in Manhattan had added a charge of murder, according to an online court docket. He's expected to be extradited to New York eventually. People are also reading... It’s unclear whether Mangione has an attorney who can comment on the allegations. Asked at Monday's arraignment whether he needed a public defender, Mangione asked whether he could “answer that at a future date.” Mangione was arrested in Altoona, Pennsylvania, after the McDonald's customer recognized him and notified an employee, authorities said. Police in Altoona, about 233 miles (375 kilometers) west of New York City, were soon summoned. This booking photo released Monday, Dec. 9, 2024, by the Pennsylvania Department of Corrections shows Luigi Mangione, a suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson. (Pennsylvania Department of Corrections via AP) They arrived to find Mangione sitting at a table in the back of the restaurant, wearing a blue medical mask and looking at a laptop, according to a Pennsylvania police criminal complaint. He initially gave them a fake ID, but when an officer asked Mangione whether he’d been to New York recently, he “became quiet and started to shake,” the complaint says. When he pulled his mask down at officers' request, “we knew that was our guy,” rookie Officer Tyler Frye said at a news conference in Hollidaysburg. New York Police Commissioner Jessica Tisch said at a Manhattan news conference that Mangione was carrying a gun like the one used to kill Thompson and the same fake ID the shooter had used to check into a New York hostel, along with a passport and other fraudulent IDs. NYPD Chief of Detectives Joseph Kenny said Mangione also had a three-page, handwritten document that shows “some ill will toward corporate America." An NYPD police officer and K-9 dog search around a lake in Central Park, Monday, Dec. 9, 2024, in New York. (AP Photo/Yuki Iwamura) A law enforcement official who wasn’t authorized to discuss the investigation publicly and spoke with The Associated Press on condition of anonymity said the document included a line in which Mangione claimed to have acted alone. “To the Feds, I’ll keep this short, because I do respect what you do for our country. To save you a lengthy investigation, I state plainly that I wasn’t working with anyone,” the document said, according to the official. It also had a line that said, “I do apologize for any strife or traumas but it had to be done. Frankly, these parasites simply had it coming.” Pennsylvania prosecutor Peter Weeks said in court that Mangione was found with a passport and $10,000 in cash — $2,000 of it in foreign currency. Mangione disputed the amount. Thompson, 50, was killed last Wednesday as he walked alone to a midtown Manhattan hotel for an investor conference. Police quickly came to see the shooting as a targeted attack by a gunman who appeared to wait for Thompson, came up behind him and fired a 9 mm pistol. Investigators have said “delay,” “deny” and “depose” were written on ammunition found near Thompson’s body. The words mimic a phrase used to criticize the insurance industry. A poster issued by the Federal Bureau of Investigation shows a wanted unknown suspect. (FBI via AP) From surveillance video, New York investigators gathered that the shooter fled by bike into Central Park, emerged, then took a taxi to a northern Manhattan bus terminal. Once in Pennsylvania, he went from Philadelphia to Pittsburgh, “trying to stay low-profile” by avoiding cameras, Pennsylvania State Police Lt. Col. George Bivens said. A grandson of a wealthy, self-made real estate developer and philanthropist, Mangione is a cousin of a current Maryland state legislator. Mangione was valedictorian at his elite Baltimore prep school, where his 2016 graduation speech lauded his classmates’ “incredible courage to explore the unknown and try new things.” He went on to earn undergraduate and graduate degrees in computer science in 2020 from the University of Pennsylvania, a spokesperson said. “Our family is shocked and devastated by Luigi’s arrest,” Mangione’s family said in a statement posted on social media late Monday by his cousin, Maryland lawmaker Nino Mangione. “We offer our prayers to the family of Brian Thompson and we ask people to pray for all involved.” An NYPD police officer and K-9 dog search around a lake in Central Park, Monday, Dec. 9, 2024, in New York. (AP Photo/Yuki Iwamura) Luigi Nicholas Mangione worked for a time for the car-buying website TrueCar and left in 2023, CEO Jantoon Reigersman said by email. From January to June 2022, Mangione lived at Surfbreak, a “co-living” space at the edge of Honolulu tourist mecca Waikiki. Like other residents of the shared penthouse catering to remote workers, Mangione underwent a background check, said Josiah Ryan, a spokesperson for owner and founder R.J. Martin. “Luigi was just widely considered to be a great guy. There were no complaints,” Ryan said. "There was no sign that might point to these alleged crimes they’re saying he committed.” At Surfbreak, Martin learned Mangione had severe back pain from childhood that interfered with many aspects of his life, from surfing to romance, Ryan said. “He went surfing with R.J. once but it didn’t work out because of his back," Ryan said, but noted that Mangione and Martin often went together to a rock-climbing gym. NYPD officers in diving suits search a lake in Central Park, Monday, Dec. 9, 2024, in New York. (AP Photo/Yuki Iwamura) Mangione left Surfbreak to get surgery on the mainland, Ryan said, then later returned to Honolulu and rented an apartment. Martin stopped hearing from Mangione six months to a year ago. Although the gunman obscured his face during the shooting, he left a trail of evidence in New York, including a backpack he ditched in Central Park, a cellphone found in a pedestrian plaza, a water bottle and a protein bar wrapper. In the days after the shooting, the NYPD collected hundreds of hours of surveillance video and released multiple clips and still images in hopes of enlisting the public’s eyes to help find a suspect. “This combination of old-school detective work and new-age technology is what led to this result today,” Tisch said at the New York news conference. ___ Scolforo reported from Altoona and Hollidaysburg, Pennsylvania. Contributing were Associated Press writers Cedar Attanasio and Jennifer Peltz in New York; Michael Rubinkam and Maryclaire Dale in Pennsylvania; Lea Skene in Baltimore and Jennifer Sinco Kelleher in Honolulu. Be the first to know Get local news delivered to your inbox!Deepen Cooperation and Create the Future Together | The 2024 SLKOR Annual Agent Seminar was successfully concluded

Ottawa, Dec. 24, 2024 (GLOBE NEWSWIRE) -- The global healthcare and medical simulation market size was valued at USD 2.38 billion in 2024 and is predicted to hit around USD 6.32 billion by 2033, a study published by Towards Healthcare a sister firm of Precedence Statistics. Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5310 Healthcare and Medical Simulation: Transforming Medical Training and Patient Safety The healthcare and medical simulation market involves the use of various technologies, products and services, and simulation software to create realistic training environments for healthcare professionals. Simulation technologies are an ideal solution to enhance medical education, training, and patient safety. Healthcare organizations are increasingly adopting human patient simulators (HPSs) to capture skills in cognitive-communication procedural performance and psychomotor processes to improve quality and practice safety by minimizing adverse events. It is a safe way to learn clinical skills without endangering patients’ lives and has become crucial in medical training. According to the World Health Organization (WHO), around 1 in every 10 patients is harmed in health care, which highlights the need for appropriate methods, such as simulation, to reduce this number. Governments, health agencies, and academic institutes worldwide have recognized the effectiveness and importance of simulation learning. Thus, they are dedicating large budgets to establishing new simulation centers. The European Union focuses on simulation through the Horizon 2020 Program. The rising demand for effective training methods in medical institutions and the increasing need for skilled healthcare professionals are expected to contribute to market expansion. Major Trends in the Healthcare and Medical Simulation Market Strong Emphasis on Patient Safety and Reducing Medical Errors: Medical errors are a leading concern in healthcare systems worldwide. Deeply rooted in the theoretical framework of simulation theory, it is an effective way to train healthcare professionals since it creates a real-life, confined training environment where personnel practice effectively. The rationale for this approach is that it minimizes the chances of making errors when solving real-life clinical problems. According to the WHO, more than 3 million deaths occur annually across the globe due to unsafe care. This underscores the critical role of simulation-based education in improving healthcare outcomes. Technological Advancements in Simulation: Ongoing advancements in simulation technology, such as virtual reality, augmented reality, and high-fidelity mannequins, are making simulations more realistic. Such innovations allow users to gain a learning experience that provides mock representations of real-life situations that help with clinical skills. The FDA recognizes the effectiveness of AR and VR in medical education and improved surgical accuracy. Furthermore, integrating AI technologies in medical simulation offers methods in which learning adapts to the user’s level in the simulation. Artificial intelligence is also improving training and decision-making to make medical education almost perfect, thereby enhancing the quality of care and patient safety. Growing Demand for Minimally Invasive Surgeries: With the growing demand for minimally invasive surgical procedures, there is an increased need for highly specialized training to ensure healthcare providers can perform these complex surgeries with precision. There is a growing need to expand access to resources aimed at mastering clinical practice abilities, which simulation platforms can meet. They otherwise provide the practitioners with opportunities to practice complex procedures, including laparoscopic surgeries, robotic surgeries, and endoscopic interventions, all without compromising the safety of the patient. Furthermore, the push for interprofessional education is encouraging the use of simulations that allow different healthcare disciplines to train together. Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership Regional Insights Technological Advancements Supported North America’s Dominance: What till 2040? North America dominated the healthcare and medical simulation market with the largest share in 2023. This is mainly due to the increased availability of advanced healthcare technology. The region, particularly the U.S., is at the forefront of technological advancements, leading to rapid innovations in simulation technologies. Early adoption of modern technologies and strong focus on patient safety further propelled the regional market growth. In addition, rising grants and funding programs by government and private organizations to implement a sophisticated simulation-based education contribute to market in the region. Asia Pacific: The Fastest-growing Region The market in Asia Pacific is anticipated to expand at the fastest growth rate in the coming years. This is mainly due to the increasing demand for healthcare simulation to enhance patient care. The increasing focus on a patient-centric approach and patient safety is encouraging the adoption of advanced healthcare training solutions, including healthcare simulation. However, simulation-based training is efficient for improving patient care and safety. Moreover, rising government initiatives to improve healthcare infrastructure can have a positive impact on the regional market. You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com Healthcare and Medical Simulation Market Segmentation By product and services , the anatomical models segment dominated the market in 2023. This is mainly due to their widespread use in medical education, training, and surgical planning. These models offer a realistic representation of human anatomy for hands-on learning and practice. By technology , the procedural rehearsal technology segment registered dominance in the market in 2023 owing to its ability to provide realistic, immersive simulations that allow medical professionals to practice complex procedures in a risk-free environment. This technology enhances skills and improves patient outcomes. By end-use , the academic institutes segment dominated the market for healthcare and medical simulation in 2023. This is mainly due to the rising number of medical students in institutions, the availability of favorable infrastructure, and the increasing focus on research in medical simulators. Competitive Landscape The healthcare simulation market is evolving rapidly with the ongoing technological advancements. Key players operating in the healthcare and medical simulation market include 3D Systems, Inc., CAE Healthcare, Inc., Simulations Plus, Inc., SGMC Health, Oxford Medical Simulation, GigXR, Inc., SimX, Medical-X, Laerdal Medical, Mentice, Gaumard Scientific, and Simulaids. These companies are focusing on bringing innovations to the market to advance healthcare education. Recent Developments In March 2024 , Wolters Kluwer Health launched two resources to advance simulation in nursing education, helping nursing students build actionable skills from classroom knowledge: a new book titled A Practical Guide for Nurse Practitioner Faculty Using Simulation in Competency-Based Education and an upcoming webinar, “Simulation in Competency-Based Nurse Practitioner Education.” In November 2023 , the College of Physicians and Surgeons of Mumbai inaugurated its state-of-the-art high-fidelity Simulation Lab. This milestone highlights the institution’s commitment to advancing medical training, fostering innovation, and enhancing clinical performance. In July 2024 , MediSim VR, a leader in healthcare simulation training technology, announced the establishment of Chennai's first Center of Excellence (CoE) VR lab at Sri Ramachandra Institute of Higher Education and Research (SRIHER). This state-of-the-art facility provides immersive, interactive VR training for medical students across the nation. Browse More Insights of Towards Healthcare: The robotic dentistry market was valued at US$ 535 million in 2023 and is projected to grow to US$ 2,585.94 million by 2034, rising at a CAGR of 15.4% from 2024 to 2034. The smart ward market was valued at US$ 3.06 billion in 2023 and is expected to reach US$ 11.83 billion by 2034, expanding at a CAGR of 13.1% from 2024 to 2034. The AI-powered retina image analysis market is rapidly advancing globally, with revenue expectations reaching hundreds of millions between 2024 and 2034. The global AI in drug discovery market was valued at US$ 1,385.01 million in 2023 and is expected to grow to US$ 10,838.70 million by 2033, at a CAGR of 23.22% from 2024 to 2033. The global healthcare IT market was valued at US$ 238.30 billion in 2023 and is projected to grow to US$ 1,404.55 billion by 2034, rising at a CAGR of 17.5% from 2024 to 2034. The global electronic health records market size is estimated at USD 28.60 billion in 2024 and is expected to grow to USD 43.66 billion by 2034, expanding at a CAGR of 4.32% from 2024 to 2034. The global cell separation technologies market was valued at USD 15.84 billion in 2024, grew to USD 18.32 billion in 2025, and is projected to reach USD 67.75 billion by 2034, expanding at a CAGR of 15.64% from 2024 to 2034. The global medical imaging informatics market was estimated at US$ 5.5 billion in 2023 and is projected to grow to US$ 11.4 billion by 2034, rising at a CAGR of 6.85% from 2024 to 2034. The global biosimulation market size was valued at USD 3.97 billion in 2024, grew to USD 4.64 billion in 2025, and is projected to reach USD 18.97 billion by 2034, expanding at a CAGR of 16.94% from 2024 to 2034. The global Artificial Intelligence (AI) in precision medicine market size is expected to grow from USD 2.74 billion in 2024 to USD 26.66 billion by 2034, at a CAGR of 25.54% between 2024 and 2034. Segments Covered in the Report By Product and Services Anatomical Models Patient Simulators High-Fidelity Simulators Medium-Fidelity Simulators Low-Fidelity Simulators Task Trainers Interventional/Surgical Simulators Laparoscopic Surgical Simulators Gynaecology Surgical Simulators Cardiac Surgical Simulators Arthroscopic Surgical Simulators Other Interventional/Surgical Simulators Endovascular Simulators Ultrasound Simulators Dental Simulators Eye Simulators Web-Based Simulation Medical Simulation Software Performance Recording Software Virtual Tutors Simulation Training Services Vendor-Based Training Educational Societies Custom Consulting and Training Services By Technology Procedure Rehearsal Technology Virtual Patient Simulation 3D Printing By End-Use Academic Institutes Hospitals Military Organizations Research Medical Device Companies Others By Region North America Asia Pacific Europe Latin America Middle East and Africa (MEA) Discover our detailed Table of Contents (TOC) for the Healthcare and Medical Simulation Market @ https://www.towardshealthcare.com/table-of-content/healthcare-and-medical-simulation-market-sizing Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5310 You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare : Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. Browse our Brand-New Journals: https://www.towardspackaging.com https://www.towardsautomotive.com https://www.precedenceresearch.com https://www.towardsdental.com For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.comThe Company achieved numerous commercial milestones in 2024, including increased profitability, launching an initial public offering, moving into new marketplaces, securing key strategic acquisitions and partnerships, and finalizing landmark carbon offset presales FORT LAUDERDALE, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the "Company”, "Zefiro”, or "ZEFI”) , an environmental services company specializing in methane abatement operations, took numerous steps in 2024 to accelerate the Company's profitability and commercial momentum. Specifically, Zefiro's success over the past twelve months can be attributed to its execution of the Company's strategy to expand its commercial footprint in critical marketplaces across North America and generate industry-leading, American Carbon Registry-approved carbon credits via an expanding, nationwide orphaned oil and gas well plugging operation. By actively advancing numerous strategic initiatives and bolstering its internal infrastructure throughout 2024, Zefiro is poised to remain at the forefront of the environmental services industry and reach yet another slate of notable accomplishments in the year ahead. The Company's 2024 highlights include: Crew members contracted by Zefiro subsidiary Plants & Goodwin on-site at an Ohio-based well plugging operation in November 2024. Readers using news aggregation services may be unable to view the link provided above. Please access SEDAR+ or the Investors section of the Company's website for a version of this press release containing links and media. Zefiro Founder and Chief Executive Officer Talal Debs commented, "From our plugging crews completing projects across the country to our expert team of carbon market specialists connecting with customers throughout the world, we have strived to invest in the resources needed to position each of our dedicated team members for success. The string of new milestones that we have been able to achieve over the past twelve months is directly linked to our senior management team's commitment to that process, and I am incredibly proud that the progress that our team has earned in 2024 will guide our positive commercial momentum well into the future.” Zefiro Chief Financial Officer Mohit Gupta commented, "2024 has been a transformative year for Zefiro, and our ability to garner sustainable, increasing returns for our investors is a direct result of the unwavering dedication and expertise of our entire team. Through consistent execution of our comprehensive, client service-oriented strategy, we have established our position as a market leader, forged a consistent pipeline of project opportunities, and helped more communities safeguard public health.” About Zefiro Methane Corp. Zefiro is an environmental services company, specializing in methane abatement. Zefiro strives to be a key commercial force towards Active Sustainability. Leveraging decades of operational expertise, Zefiro is building a new toolkit to clean up air, land, and water sources directly impacted by methane leaks. The Company has built a fully integrated ground operation driven by an innovative monetization solution for the emerging methane abatement marketplace. As an originator of high-quality U.S.-based methane offsets, Zefiro aims to generate long-term economic, environmental, and social returns. On behalf of the Board of Directors of the Company, ZEFIRO METHANE CORP. "Talal Debs” Talal Debs, Founder & CEO For further information, please contact: Zefiro Investor Relations 1 (800) 274-ZEFI (274-9334) [email protected] For media inquiries, please contact: Rich Myers - Profile Advisors (New York) [email protected] +1 (347) 774-1125 Forward-Looking Statements This news release contains "forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information is often, but not always, identified by the use of words such as "seeks”, "believes”, "plans”, "expects”, "intends”, "estimates”, "anticipates” and statements that an event or result "may”, "will”, "should”, "could” or "might” occur or be achieved and other similar expressions. In particular, this news release contains forward-looking information including statements regarding: the Company's intention to reduce emissions from end-of-life oil and gas wells and eliminate methane gas; the Company's partnerships with industry operators, state agencies, and federal governments; the Company's expectations for continued increases in revenues and EBITDA growth as a result of these partnerships; the Company's intentions to build out its presence in the United States; the anticipated federal funding for orphaned well site plugging, remediation and restoring activities; the Company's expectations to become a growing environmental services company; the Company's ability to provide institutional and retail investors alike with the opportunity to join the Active Sustainability movement; the Company's ability to generate long-term economic, environmental, and social returns; and other statements regarding the Company's business and the industry in which the Company operates. The forward-looking information reflects management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include, but are not limited to: (i) adverse general market and economic conditions; (ii) changes to and price and volume volatility in the carbon market; (iii) changes to the regulatory landscape and global policies applicable to the Company's business; (iv) failure to obtain all necessary regulatory approvals; and (v) other risk factors set forth in its Prospectus dated April 8, 2024 under the heading "Risk Factors”. The Company operates in a rapidly evolving environment where technologies are in the early stage of adoption. New risk factors emerge from time to time, and it is impossible for the Company's management to predict all risk factors, nor can the Company assess the impact of all factors on Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. Forward-looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including, but not limited to, the assumption that general business and economic conditions will not change in a materially adverse manner. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The forward-looking information included in this news release is made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. Statement Regarding Third-Party Investor Relations Firms Disclosures relating to investor relations firms retained by Zefiro Methane Corp. can be found under the Company's profile on SEDAR+ at www.sedarplus.ca/ . A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a438934-f40c-440b-b8a7-af17ae78c414

US President-elect Donald Trump has the Panama Canal in his sights, blasting the "exorbitant prices and rates of passage" levied on US ships, and threatening to retake control of the US-built shipping route, which connects the Atlantic and Pacific oceans. "The fees being charged by Panama are ridiculous, especially knowing the extraordinary generosity that has been bestowed to Panama by the US," Trump wrote on his Truth Social platform . Accusing Panama of "ripping off" the US, Trump added that the canal "was not given for the benefit of others, but merely as a token of co-operation with us and Panama. If the principles, both moral and legal, of this magnanimous gesture of giving are not followed, then we will demand that the Panama Canal be returned to us, in full, and without question." Why was the Panama Canal built? The 51-mile waterway, through the middle of Panama, connects the Atlantic and the Pacific oceans, and allows ships to avoid the long, treacherous journey around the southern tip of South America. Creating such a passageway was the "elusive goal of several empires that had colonies in the Americas", said CNN . The US took control of a strip of land and began construction in 1904, after backing a revolt that helped Panama win its independence from Colombia. When the canal was completed in 1914, it "cemented the US's status as an engineering and technological superpower" – despite the "enormous human cost". An estimated 5,600 people died during its construction. Now, up to 14,000 ships pass through the canal every year, transporting cargo worth about $270 billion (£214 billion). And the US is its biggest customer. Who owns the Panama Canal? Ownership of the canal has long been a bone of contention. After the canal opened, the US controlled it, to the exclusion of Panamanians – which, over the years, "created tensions between locals and US visitors", said The Guardian . These tensions reached critical mass in 1964 when anti-US riots broke out in the canal zone, leading to several deaths and a brief severing of diplomatic ties between the two countries. In 1977, the US began ceding control back to Panama, under a treaty signed by President Jimmy Carter. But the move wasn't supported by all, with then-presidential candidate Ronald Reagan stating that "the people of the United States" are "the rightful owners of the Canal Zone", said CNN. After a period of joint custody and official neutrality – "marred by a 1989 US invasion" to overthrow Manuel Noriega – Panama took full control in 1999, and has since operated the canal through the Panama Canal Authority. Trump has now suggested that the canal is in danger of falling into the "wrong hands" – an apparent reference to China, the canal's second-biggest customer. A "Chinese company, based in Hong Kong, controls two of the five ports next to the canal", said The Guardian. After Trump raised the issue again in a speech on Sunday, Panama's President José Raúl Mulino said that his country's sovereignty and independence were "non-negotiable", and that China had "no influence" or control over the canal. "Every square metre of the Panama Canal and its adjacent zones is part of Panama, and it will continue to be," Mulino said in a video statement. Trump responded: "We'll see about that!" Why is Trump interested in the Panama Canal? The canal is "running dry" , said the BBC . A lack of rain and the El Niño weather phenomenon mean that water levels in Lake Gatún, which feeds the canal, are "falling critically low". This drought has "hampered the canal's ability to move ships between the Atlantic and Pacific oceans", said Bloomberg . As part of its water-saving measures, Panama has reduced the number of ships allowed to pass through, and the weight they are allowed to carry, exacerbating existing pressures on supply chains. Despite the restrictions, the canal's profits increased by about 9.5% in the year ending in September, said Reuters , to $3.45 billion (£2.7 billion). But authorities have imposed higher and higher fees to pass through the canal, and this "appears to form one part of Trump's issue", said CNN . His other claim that China is seeking to exert more control "is not without merit", either – China's influence in the area around the canal has grown since Panama vowed in 2017 not to maintain any official ties with Taiwan . Trump also has form for "threatening to take or encroach on territory belonging to a friendly foreign power". He has "taunted" Canadian Prime Minister Justin Trudeau by suggesting that Canada should be made the 51st US state, and, during his first term, he "repeatedly floated the idea of the US buying Greenland from Denmark" – a notion he also "resurrected" last weekend. His "not-so-subtle threats" are a reminder that Trump "does not always see the sovereignty of other nations' borders as sacrosanct", said The New York Times . Instead, he displays "the instincts of a real-estate developer who suddenly has the power of the world's largest military" to back him up.FILE PHOTO: This handout photo taken and released on December 7, 2024, by the South Korean Presidential Office shows South Korea’s President Yoon Suk Yeol bowing after the end of his address at the Presidential Office in Seoul. – Yoon was slapped with a travel ban on December 9, the justice ministry said, less than a week after plunging South Korea into chaos by briefly imposing martial law. (Photo by Handout / South Korean Presidential Office / Agence France-Presse) SEOUL — South Korea’s President Yoon Suk Yeol was banned from traveling abroad Monday, the justice ministry said, less than a week after he plunged the country into chaos by briefly imposing martial law . Yoon sent special forces and helicopters to parliament on the night of December 3 before lawmakers forced him to rescind the order by rejecting his decree. The unpopular leader narrowly survived an impeachment motion in parliament Saturday even as huge crowds braved freezing temperatures to call for his ouster. Despite remaining in office, a clutch of investigations has been closing in on Yoon and his close allies, including a probe for alleged insurrection. The ministry of justice confirmed on Monday that Yoon had become the first sitting South Korean president to be banned from leaving the country. A lawmaker was asked at a Monday parliamentary hearing whether Yoon had been banned from international travel. “Yes, that’s right,” replied Bae Sang-up, an immigration services commissioner at the ministry. Also under travel bans for their roles in last week’s events are former defense minister Kim Yong-hyun – currently in detention – and ex-interior minister Lee Sang-min. READ: South Korean opposition plans new impeachment push General Park An-su, the officer in charge of the martial law operation, and defense counterintelligence commander Yeo In-hyung are also barred from leaving South Korea. Investigators hauled Park in for further questioning Monday, and Yonhap news agency reported that prosecutors had asked for a warrant for Kim’s formal arrest. The impeachment push failed to pass after members of Yoon’s own People Power Party (PPP) walked out of parliament, depriving it of the necessary two-thirds majority. The PPP says that in exchange, the 63-year-old Yoon has agreed to hand power to the prime minister and party chief, prompting howls of protest from the opposition. “This is an unlawful, unconstitutional act of a second insurrection and a second coup,” Democratic Party floor leader Park Chan-dae said. FILE PHOTO: Soldiers try to enter the National Assembly building in Seoul on December 4, 2024, after South Korean President Yoon Suk Yeol declared martial law. – Yoon was slapped with a travel ban on December 9, the justice ministry said, less than a week after plunging South Korea into chaos by briefly imposing martial law. (Photo by Jung Yeon-je / Agence France-Presse) Under South Korea’s constitution, the president remains head of government and commander in chief of the army unless he or she is incapacitated, resigns or steps down. In such a case, power would then be handed to the prime minister on an interim basis until elections could be held. Claiming Yoon can remain in office but has delegated his powers to the prime minister and leader of his ruling PPP – who is not an elected official – is “a blatant constitutional violation with no legal basis,” Park said. “Their attitude of placing themselves above the constitution mirrors that of insurrectionist Yoon Suk Yeol,” he said. South Korea’s ally the United States indicated it would still deal with Yoon but said it “will keep lines of communication open with all relevant parties”. “President Yoon is the president of Korea, and the political process in Korea will play out, as it should, under Korea’s laws and Korea’s constitution,” State Department spokesman Matthew Miller told reporters. FILE PHOTO: Extra edition newspapers are displayed at a subway gate in downtown Seoul on December 4, 2024, after martial law was lifted. – Yoon was slapped with a travel ban on December 9, the justice ministry said, less than a week after plunging South Korea into chaos by briefly imposing martial law. (Photo by Jung Yeon-je / Agence France-Presse) The defense ministry confirmed Monday that the embattled Yoon still oversees the country’s security apparatus, despite the apparent power vacuum in a country that remains technically at war with nuclear-armed North Korea. “Legally, (control of military forces) currently lies with the commander in chief,” defence ministry spokesperson Jeon Ha-kyou said. Yoon has apologised for “anxiety and inconvenience” caused by his declaration of martial law but has not stepped down, saying instead he would entrust decisions about his fate to his party. READ: South Korea president clings to power after martial law U-turn He also said he would accept all political and legal responsibility for the martial law fiasco. There is no constitutional basis supporting the ruling party’s claim that Yoon can stay in office but hand over his power to unelected party officials, said Kim Hae-won, a constitutional law professor at Pusan National University Law School. “It seems to resemble an unconstitutional soft coup,” he told Agence France-Presse. “If there are issues with the president, there are ways laid out in the constitution such as suspending the president from his duties, and then move on to proceedings set out in the constitution, such as impeachment,” he said. Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . The opposition has already said they would try again to impeach Yoon, with leader Lee Jae-myung saying another vote would be held Saturday.

Suspect in UnitedHealthcare CEO killing charged with murder in New York, court records showNatixis Advisors LLC Buys 6,467 Shares of Natera, Inc. (NASDAQ:NTRA)